Search results for "FDA update"
New labels warn against sharing multi-dose insulin pens
In an effort to reduce the risk of infection spread, the FDA recently required additional label warnings about sharing of multi-dose diabetes pen devices, which are intended for single patient use only.
https://diabetes.acponline.org/archives/2015/03/13/9.htm
13 Mar 2015
Olmesartan passes safety review
The benefits of the angiotensin-receptor blocker olmesartan continue to outweigh the risks for diabetic patients, according to the FDA.
https://diabetes.acponline.org/archives/2014/07/11/8.htm
11 Jul 2014
Inhaled insulin approved
Afrezza, a rapid-acting, inhaled human insulin, was recently approved by the FDA to treat diabetes in adults.
https://diabetes.acponline.org/archives/2014/07/11/7.htm
11 Jul 2014
New GLP-1 receptor agonist approved
Albiglutide (Tanzeum), a glucagon-like peptide-1 (GLP-1) receptor agonist, was recently approved by the FDA to treat type 2 diabetes in adults, along with diet and exercise.
https://diabetes.acponline.org/archives/2014/05/09/8.htm
9 May 2014
Extended-release metformin recalled due to impurity
Companies recently recalled metformin hydrochloride for extended-release oral suspension and metformin hydrochloride extended-release tablets USP due to excess amounts of N-nitrosodimethylamine.
https://diabetes.acponline.org/archives/2020/10/09/10.htm
9 Oct 2020
Alert warns about cybersecurity risk with insulin pump system
A potential issue with the Medtronic MiniMed 600 Series Insulin Pump System's communication protocol could allow unauthorized access to the device, the FDA said.
https://diabetes.acponline.org/archives/2022/10/14/9.htm
14 Oct 2022
More metformin recalled due to nitrosamine impurity
The recall includes 33 lots of metformin hydrochloride extended-release tablets USP (750 mg) manufactured in India and distributed in the U.S.
https://diabetes.acponline.org/archives/2022/01/14/6.htm
14 Jan 2022
Insulin recalled due to potential missing label
Mylan Pharmaceuticals Inc. is recalling one batch of insulin glargine injection due to the potential for a missing label on some pens within a labeled carton.
https://diabetes.acponline.org/archives/2022/02/11/6.htm
11 Feb 2022
Follow-on insulin lispro approved
The injection is approved to improve glucose control in patients ages three years and older with type 1 diabetes and in adult patients with type 2 diabetes.
https://diabetes.acponline.org/archives/2018/01/12/8.htm
12 Jan 2018
Drug approved to delay onset of stage 3 type 1 diabetes
The first-in-class therapy, indicated in adults and pediatric patients ages 8 years and older who currently have stage 2 type 1 diabetes, is administered by IV infusion once daily for 14 consecutive days.
https://diabetes.acponline.org/archives/2022/12/09/11.htm
9 Dec 2022